Skip to content

Rapid, Cost-Effective T Cell Therapy Manufacturing

Next-generation vector technology, delivered in partnership with Syenex

CliniMACS Prodigy automated cell processing system in the Made Scientific process development lab
PartnershipTechnology and supply
PlatformMadeFast™ with RapidCell™
Initial focusCAR-T and TCR workflows
SitesPrinceton, NJ and East Norriton, PA

MadeFast™, Powered by Syenex RapidCell™

A Next-Generation Framework for Reducing Manufacturing Cost, Complexity, and Time

MadeFast™ is Made Scientific's single-step CAR-T manufacturing platform, designed to consolidate enrichment, activation, and transduction into a single step early in the manufacturing process. MadeFast is technology-agnostic by design: it defines the streamlined workflow, while the specific enabling vector can be selected based on performance and program needs. In its first configuration, MadeFast integrates Syenex's RapidCell™, engineered to simultaneously activate and transduce T cells, to deliver a faster, simpler, and more cost-effective path from development through GMP manufacturing.

  • Why it matters: Conventional CAR-T manufacturing requires separate enrichment, activation, and transduction steps that add cost, time, and variability
  • What’s different: RapidCell combines T cell activation and transduction into a single step, eliminating the need for separate activation reagents and potentially removing the T cell enrichment step entirely 
  • Where we are: Initial proof-of-concept data demonstrate superior transduction efficiency and comparable or higher CAR+ cell yields versus conventional methods
  • What’s next: Customer-accessible MadeFast manufacturing process under active development

“We’re thrilled to partner with Made Scientific to demonstrate how our UltraCell™ and RapidCell™ systems can redefine T cell therapy manufacturing. Together we’re showing how advanced delivery engineering can break through scalability and cost barriers, accelerating the path to life-saving therapies.”

Jay Rosanelli, Co-Founder and CEO of Syenex

How RapidCell Technology Fits into Cell Therapy Manufacturing

Initial focus: CAR-T and TCR workflows

The MadeFast platform is designed to integrate directly into existing cell therapy manufacturing workflows, replacing multiple upstream processing steps with a single, consolidated operation. In its first configuration, MadeFast uses Syenex's RapidCell as the vector for the combined activation-transduction step.

  • Consolidate activation and transduction to reduce process complexity and operator touchpoints
  • Enable transduction of non-enriched cell populations, potentially eliminating CD4/CD8 selection
  • Maintain product quality with high viability, balanced T cell subsets, and strong CAR expression at harvest

What Clients Can Expect

A simplified manufacturing workflow

Fewer process interventions, less hands-on labor, and a shorter critical path from apheresis to drug product. In total, MadeFast compresses the manufacturing timeline to approximately two days, versus 8–10 days for conventional autologous CAR-T processes.

Higher transduction efficiency at lower vector doses

Proof-of-concept data demonstrate that RapidCell achieves higher CAR expression and MFI than conventional lentiviral transduction at equivalent MOIs, a direct lever for reducing cost of goods through lower vector consumption.

A pathway to eliminate T cell enrichment

Initial data show RapidCell can transduce unfractionated PBMCs efficiently, supporting the feasibility of removing the CD4/CD8 selection step. Eliminating enrichment reduces reagent costs, processing time, and cell loss.

CDMO execution from development through GMP

Made Scientific provides end-to-end process development, tech transfer, and GMP manufacturing services optimized for the MadeFast workflow. Flexible engagement models support programs from early feasibility through clinical and commercial supply.

Why Partner with Made Scientific + Syenex

Syenex RapidCell: next-gen vector technology for T cell therapies

  • Lentiviral and retroviral vector systems engineered for simultaneous activation and transduction
  • Projected to meaningfully reduce cost of goods per dose and shorten vein-to-vein time through process consolidation, fewer operator touchpoints, and lower vector consumption

Integrated CDMO services, built for rapid manufacturing

  • GMP-ready process development, technology transfer, and manufacturing at Made Scientific's facilities in Princeton, New Jersey and East Norriton, Pennsylvania
  • Phase-appropriate quality systems and documentation aligned with U.S. FDA and EU regulatory requirements
  • Flexible partnership models, from fee-for-service to dedicated capacity, tailored to program stage
  • Structured comparability protocols to support transition from conventional to MadeFast manufacturing
Cover of the MadeFast™ single-step CAR-T manufacturing white paper

Proof-of-Concept: RapidCell Collaboration Results

In their first collaboration study, Made Scientific evaluated Syenex's RapidCell Lentiviral Vector as the enabling technology for a consolidated, single-step CAR-T manufacturing workflow. The results demonstrate measurable advantages in transduction efficiency, CAR+ cell yield, and process simplicity, establishing RapidCell as a strong candidate within Made Scientific's MadeFast platform.

Key findings

  • 97%+ CAR transduction in unfractionated PBMCs without CD4/CD8 enrichment
  • 30% more viable CAR+ cells at harvest versus conventional methods at MOI = 1, supporting reduced vector consumption and lower cost per dose
  • ≥97% viability across all conditions at Day 8 harvest (97–99.5%)
  • Balanced CD4/CD8 ratios preserved across all experimental conditions
  • Higher per-cell CAR density (MFI) than control vector at every MOI tested

More partners

See the full partner network

RoosterBio logo

RoosterBio

MSC and extracellular vesicle platforms integrated into Made Scientific’s development and manufacturing services, from process development through commercial supply.

Read the announcement
Pluristyx logo

Pluristyx

Clinical-grade iPSC lines and derivative cell types paired with Made Scientific’s process development and manufacturing expertise to support progression toward the clinic.

Explore the partnership
Streamline Bio logo

Streamline Bio

Exclusive Early Adopter Program for the co-development, integration, and validation of AI-driven robotic automation for cell therapy manufacturing.

Explore the partnership
CARR Biosystems logo

CARR Biosystems

UniFuge® single-use centrifugation integrated across Made Scientific's Princeton and East Norriton facilities for scalable MSC manufacturing.

Explore the partnership
Cell therapy drug product bags loaded in a Terumo BCT Finia fill system
Made Scientific - Interactive Background

Put MadeFast to Work for Your Program

Tell us about your CAR-T or TCR program and timeline. We’ll show you how MadeFast with RapidCell™ could simplify your manufacturing workflow.